Neoleukin Therapeutics (NLTX) Competitors $22.64 +0.57 (+2.56%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends NLTX vs. CRMD, ANAB, XERS, ABVX, MGTX, RNAC, TKNO, GLUE, CDXC, and ORGOShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include CorMedix (CRMD), AnaptysBio (ANAB), Xeris Biopharma (XERS), ABIVAX Société Anonyme (ABVX), MeiraGTx (MGTX), Cartesian Therapeutics (RNAC), Alpha Teknova (TKNO), Monte Rosa Therapeutics (GLUE), ChromaDex (CDXC), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. CorMedix AnaptysBio Xeris Biopharma ABIVAX Société Anonyme MeiraGTx Cartesian Therapeutics Alpha Teknova Monte Rosa Therapeutics ChromaDex Organogenesis CorMedix (NASDAQ:CRMD) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings. Do analysts rate CRMD or NLTX? CorMedix presently has a consensus target price of $15.80, suggesting a potential upside of 84.36%. Given CorMedix's stronger consensus rating and higher probable upside, equities analysts plainly believe CorMedix is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CRMD or NLTX more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat CorMedix's return on equity.Company Net Margins Return on Equity Return on Assets CorMedixN/A -79.21% -64.68% Neoleukin Therapeutics N/A -37.22%-30.91% Does the media refer more to CRMD or NLTX? In the previous week, CorMedix had 8 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 9 mentions for CorMedix and 1 mentions for Neoleukin Therapeutics. CorMedix's average media sentiment score of 0.51 beat Neoleukin Therapeutics' score of 0.00 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neoleukin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, CRMD or NLTX? CorMedix has higher revenue and earnings than Neoleukin Therapeutics. CorMedix is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$12.26M42.41-$46.34M-$0.81-10.58Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.28 Do insiders & institutionals believe in CRMD or NLTX? 34.2% of CorMedix shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 5.2% of CorMedix shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, CRMD or NLTX? CorMedix has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Does the MarketBeat Community prefer CRMD or NLTX? Neoleukin Therapeutics received 27 more outperform votes than CorMedix when rated by MarketBeat users. However, 74.19% of users gave CorMedix an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformCorMedixOutperform Votes2374.19% Underperform Votes825.81% Neoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% SummaryCorMedix beats Neoleukin Therapeutics on 11 of the 16 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$212.77M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E Ratio-7.2810.5089.8217.18Price / SalesN/A195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book2.045.094.784.78Net Income-$57.56M$151.83M$120.23M$225.60M7 Day Performance-3.70%-2.13%-1.92%-1.23%1 Month Performance47.68%-3.10%11.49%3.36%1 Year Performance53.08%11.54%30.57%16.60% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$22.64+2.6%N/A+532.5%$212.77MN/A-7.2890News CoverageHigh Trading VolumeCRMDCorMedix1.8419 of 5 stars$8.35-0.4%$15.20+82.0%+147.0%$506.65M$12.26M-10.3130Analyst ForecastNews CoveragePositive NewsANABAnaptysBio2.3125 of 5 stars$16.57+6.3%$45.09+172.1%-25.4%$504.23M$17.16M-2.80100Analyst ForecastXERSXeris Biopharma3.6033 of 5 stars$3.38+3.0%$4.87+44.0%+73.6%$503.89M$163.91M-7.67290News CoveragePositive NewsABVXABIVAX Société Anonyme2.1863 of 5 stars$7.86+10.5%$38.67+391.9%-27.6%$497.92MN/A0.0061Positive NewsGap DownMGTXMeiraGTx3.8637 of 5 stars$6.36+3.9%$23.50+269.5%+25.3%$497.05M$13.93M-5.30300News CoverageRNACCartesian Therapeutics2.2994 of 5 stars$19.25+3.0%$43.00+123.4%-6.3%$489.34M$26M-0.3537Analyst ForecastNews CoverageTKNOAlpha Teknova0.4718 of 5 stars$8.83+10.0%$5.00-43.4%+124.1%$470.73M$36.68M-11.73240Gap UpGLUEMonte Rosa Therapeutics1.9132 of 5 stars$7.61+0.7%$16.00+110.2%+28.3%$467.54M$14.98M-4.1390Analyst DowngradeNews CoverageCDXCChromaDex4.5929 of 5 stars$6.11-0.2%$8.00+30.9%+283.9%$466.70M$91.67M620.00106Analyst DowngradeORGOOrganogenesis4.222 of 5 stars$3.52+3.5%$5.33+51.5%-20.6%$466.68M$433.14M-56.67950 Related Companies and Tools Related Companies CorMedix Alternatives AnaptysBio Alternatives Xeris Biopharma Alternatives ABIVAX Société Anonyme Alternatives MeiraGTx Alternatives Cartesian Therapeutics Alternatives Alpha Teknova Alternatives Monte Rosa Therapeutics Alternatives ChromaDex Alternatives Organogenesis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NLTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLTX Stock Alerts